Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor

Status Recruiting

Clinical Trial Summary

Fibroblast froth factors (FGFs) are humoral factors identified by their ability to stimulate cell proliferation1. They play different roles in the regulation of cell proliferation, differentiation and function. Most FGF family members act as paracrine factors. But FGF19(FGF19) subfamily members, including FGF19, 21, and 23, work as endocrine factors to regulate bile acid, carbohydrate and phosphate metabolism2. Of these, FGF23 plays an important role in phosphate and bone metabolism3. FGF23 gene encodes 251 amino acids, including a 24-amino acid signal peptide4. The secreted FGF23 is a protein consisted of 227 amino acids. It works by binding to a Klotho-FGF receptor 1c (FGF1c) complex5. FGF suppresses the expression of type 2a and 2c sodium-phosphate cotransporters, which mediate phosphate reabsorption in proximal tubules.6 FGF23 decreases 25-hydroxyvitamin D-1α-hydroxylase expression and enhances 25-hydroxyvitamin D-24-hydroxylase expression6. Therefore, FGF23 reduces serum 1,25-dihydroxyvitamin D〔1,25(OH)2D〕, which stimulates intestinal calcium and phosphate absorption. FGF23 decreases serum phosphate through the above mechanisms FGF23 over-expression might result in hypophosphatemic rickets and osteomalacia.

Tumor induced osteomalacia (TIO) is a paraneoplastic syndrome usually caused by benign phosphaturic mesenchymal tumors. Symptoms are nonspecific, such as general weakness, fatigue, and bone pain. Sometimes fracture may occurs. The responsible tumors are sometimes small and difficult to detect. Tumors secrete FGF23. FGF23 reduced phosphate reabsorption in the proximal tubules and decrease 1,25(OH)2D levels, which result in hypophosphatemia and then osteomalacia.

The investigators would like to observe the changes of FGF23 in patients who receive operation or medical treatment and hope this will benefit future treatment.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01660308
Study type	Observational
Source	National Taiwan University Hospital
Contact	Shyang-Rong Shih, PhD
Email	srshih@ntu.edu.tw
Status	Recruiting
Phase	N/A
Start date	June 2011
Completion date	August 2016

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04519762` - Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU	Phase 4
Enrolling by invitation	`NCT04502784` - Investigation of Hypophosphataemia Following Intravenous Iron
Completed	`NCT03529058` - Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU
Terminated	`NCT01011114` - Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant	N/A
Completed	`NCT05098249` - Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia	Phase 4
Not yet recruiting	`NCT06350955` - IV Iron-induced Hypophosphatemia After RYGB	Phase 4
Completed	`NCT00688077` - FGF-23 Suppressibility by Calcitonin	N/A
Recruiting	`NCT04814641` - Hypophosphatemia and Bronchiolitis
Active, not recruiting	`NCT03976440` - Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study
Recruiting	`NCT05909722` - Validation of the GIDS and Description of Phosphate Disorders
Completed	`NCT03581591` - Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets	Phase 3
Completed	`NCT03740802` - Hypophosphatemia as a Predictor in Surgical Resuscitation Sepsis
Suspended	`NCT03771105` - The Impact of Phosphate Metabolism on Healthy Aging	Early Phase 1
Active, not recruiting	`NCT06112236` - Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia
Completed	`NCT03489993` - FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
Completed	`NCT00975000` - Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients	Phase 3
Withdrawn	`NCT02837523` - Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Not yet recruiting	`NCT06344546` - Metabolic Pathway Analysis in Intensive Care Unit Patients With Refeeding Syndrome

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms